Publication: Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: data from the Turkish Oncology Group
dc.contributor.coauthor | Unal, Caglar | |
dc.contributor.coauthor | Azizy, Abdulmunir | |
dc.contributor.coauthor | Karabulut, Senem | |
dc.contributor.coauthor | Tastekin, Didem | |
dc.contributor.coauthor | Akyildiz, Arif | |
dc.contributor.coauthor | Yasar, Serkan | |
dc.contributor.coauthor | Yalcin, Suayib | |
dc.contributor.coauthor | Coban, Eyup | |
dc.contributor.coauthor | Evrensel, Turkkan | |
dc.contributor.coauthor | Kalkan, Ziya | |
dc.contributor.coauthor | Oruc, Zeynep | |
dc.contributor.coauthor | Derin, Sumeyra | |
dc.contributor.coauthor | Turna, Zeynep Hande | |
dc.contributor.coauthor | Bayram, Dogan | |
dc.contributor.coauthor | Kos, Fahriye Tugba | |
dc.contributor.coauthor | Sendur, Mehmet Ali Nihat | |
dc.contributor.coauthor | Sever, Nadiye | |
dc.contributor.coauthor | Ercelep, Oezlem | |
dc.contributor.coauthor | Seyyar, Mustafa | |
dc.contributor.coauthor | Kefeli, Umut | |
dc.contributor.coauthor | Uygun, Kazim | |
dc.contributor.coauthor | Ozcelik, Melike | |
dc.contributor.coauthor | On, Sercan | |
dc.contributor.coauthor | Sanli, Ulus Ali | |
dc.contributor.coauthor | Canaslan, Kubra | |
dc.contributor.coauthor | Unek, Ilkay Tuba | |
dc.contributor.coauthor | Yucel, Kadriye Bir | |
dc.contributor.coauthor | Ozdemir, Nuriye | |
dc.contributor.coauthor | Yazici, Ozan | |
dc.contributor.coauthor | Guzel, Halil Goksel | |
dc.contributor.coauthor | Salim, Derya Kivrak | |
dc.contributor.coauthor | Goksu, Sema Sezgin | |
dc.contributor.coauthor | Tatli, Ali Murat | |
dc.contributor.coauthor | Ordu, Cetin | |
dc.contributor.coauthor | Selvi, Oguzhan | |
dc.contributor.coauthor | Sakin, Abdullah | |
dc.contributor.coauthor | Buyukbayram, Mehmet Emin | |
dc.contributor.coauthor | Dursun, Bengu | |
dc.contributor.coauthor | Urun, Yuksel | |
dc.contributor.coauthor | Arak, Haci | |
dc.contributor.coauthor | Agdas, Gozde | |
dc.contributor.coauthor | Ugrakli, Muzaffer | |
dc.contributor.coauthor | Hendem, Engin | |
dc.contributor.coauthor | Eryilmaz, Melek Karakurt | |
dc.contributor.coauthor | Bilgin, Burak | |
dc.contributor.coauthor | Topcu, Atakan | |
dc.contributor.coauthor | Simsek, Melih | |
dc.contributor.coauthor | Buyuksimsek, Mahmut | |
dc.contributor.coauthor | Akay, Busra | |
dc.contributor.coauthor | Erdal, Gulcin Sahingoz | |
dc.contributor.coauthor | Karatas, Fatih | |
dc.contributor.coauthor | Caglayan, Melek | |
dc.contributor.coauthor | Kahvecioglu, Fatma Akdag | |
dc.contributor.coauthor | Demirci, Ayse | |
dc.contributor.coauthor | Paksoy, Nail | |
dc.contributor.coauthor | Cetin, Bulent | |
dc.contributor.coauthor | Gumus, Mahmut | |
dc.contributor.coauthor | Ak, Naziye | |
dc.contributor.coauthor | Aydinalp, Yasemin | |
dc.contributor.coauthor | Paydas, Semra | |
dc.contributor.coauthor | Guven, Deniz Can | |
dc.contributor.coauthor | Kilickap, Saadettin | |
dc.contributor.coauthor | Saglam, Sezer | |
dc.contributor.department | KUH (Koç University Hospital) | |
dc.contributor.kuauthor | Alan, Özkan | |
dc.contributor.schoolcollegeinstitute | KUH (KOÇ UNIVERSITY HOSPITAL) | |
dc.date.accessioned | 2025-01-19T10:27:56Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).Methods: We conducted a multicenter retrospective study analyzing the data of 308 patients with metastatic NETs treated with CAPTEM between 2010 and 2022 in 34 different hospitals across various regions of Turkey.Results: The median follow-up time was 41.0 months (range: 1.7-212.1), and the median age was 53 years (range: 22-79). Our results across the entire patient cohort showed a median progression-free survival (PFS) of 10.6 months and a median overall survival (OS) of 60.4 months. First-line CAPTEM treatment appeared more effective, with a median PFS of 16.1 months and a median OS of 105.8 months (median PFS 16.1, 7.9, and 9.6 months in first-, second-and =third-line respectively, P = .01; with median OS values of 105.8, 47.2, and 24.1 months, respectively, P = .003) In terms of ORR, the first-line treatment again performed better, resulting in an ORR of 54.7% compared to 33.3% and 30.0% in the second and third or higher lines, respectively (P < .001). Grade 3-4 side effects occurred only in 22.5% of the patients, leading to a discontinuation rate of 9.5%. Despite the differences in outcomes based on treatment line, we did not observe a significant difference in terms of side effects between the first and subsequent lines of treatment.Conclusions and Relevance: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 10 | |
dc.description.openaccess | Green Published, gold | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | The authors sincerely thank Associate Prof. Phd Tomris Duymaz for her valuable contributions to this study. | |
dc.description.volume | 28 | |
dc.identifier.doi | 10.1093/oncolo/oyad257 | |
dc.identifier.eissn | 1549-490X | |
dc.identifier.issn | 1083-7159 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-8517408016 | |
dc.identifier.uri | https://doi.org/10.1093/oncolo/oyad257 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/25641 | |
dc.identifier.wos | 1063354900001 | |
dc.keywords | Capecitabine | |
dc.keywords | CAPTEM | |
dc.keywords | Neuroendocrine neoplasia | |
dc.keywords | Neuroendocrine tumors | |
dc.keywords | Temozolomide | |
dc.language.iso | eng | |
dc.publisher | Oxford Univ Press | |
dc.relation.grantno | The authors sincerely thank Associate Prof. Phd Tomris Duymaz for her valuable contributions to this study. | |
dc.relation.ispartof | Oncologist | |
dc.subject | Oncology | |
dc.title | Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: data from the Turkish Oncology Group | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Alan, Özkan | |
local.publication.orgunit1 | KUH (KOÇ UNIVERSITY HOSPITAL) | |
local.publication.orgunit2 | KUH (Koç University Hospital) | |
relation.isOrgUnitOfPublication | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isOrgUnitOfPublication.latestForDiscovery | f91d21f0-6b13-46ce-939a-db68e4c8d2ab | |
relation.isParentOrgUnitOfPublication | 055775c9-9efe-43ec-814f-f6d771fa6dee | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 055775c9-9efe-43ec-814f-f6d771fa6dee |
Files
Original bundle
1 - 1 of 1